The long-term trend of the EPS is an important number as it indicates the present value of InVivo Therapeutics Corp.. The EPS growth rate, as it is usually called, is typically displayed as a percentage, which at this time is hard to estimate, but EPS was -49.60% over the last twelve months. The higher the EPS growth rate, the higher the value that is added to shareholders and a good reflection on the performance of the management at InVivo Therapeutics Corp..



InVivo Therapeutics Corp. trades as part of the biotechnology industry and trades as part of the healthcare sector. The company CEO is Richard M. Toselli. InVivo Therapeutics Corp is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries.

Previous Intraday Performance:

The NVIV shares had a previous change of -2.44% which opened at 2.02 and closed at 2.00. It moved to an intraday high of 2.05 and a low of 2.00.

SeekingAlpha:  InVivo Therapeutics up 8% on collaborating with privately held Q Therapeutics

Historical Performance:

Over the last five trading days, NVIV shares returned -1.48% and in the past 30 trading days it returned 3.63%. Over three months, it changed 1.01%. In one year it has changed -94.67% and within that year its 52-week high was 38.75 and its 52-week low was 1.63. NVIV stock is 22.65% above its 52 Week Low.

Our calculations result in a 200 day moving average of 8.09 and a 50 day moving average of 1.97. Right now, NVIV stock is trading -75.29% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

Business Wire:  InVivo Therapeutics Announces Joint Research Collaboration with Q Therapeutics, Inc.

Liquidity:

The company has a market cap of $15.5m with 7.8m shares outstanding and a float of 0 shares. Trading volume was 53,880 shares and has experienced an average volume of 83,721 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for InVivo Therapeutics Corp. was -20.15 which ended on 31st of December 2017.

Below was the last reported quarterly earnings per share:
06-30-2018:  -7.48
03-31-2018:  -3.34
12-31-2017:  -3.25
09-30-2017:  -7.00



Base on our calculations, the intrinsic value per share is 32.47, which means it might be undervalued and has a margin of safety of 93.84%

Indicators Also to Watch:

Based on the latest filings, there is 11.50% of institutional ownership. Short-interest was 227,769, which was 2.93% of shares outstanding. The short-interest ratio or days-to-cover ratio was 3.09. This stock has some short interest, but it might be normal and no need to worry if long the position.

I calculated the beta to be 2.14

Business Wire:  InVivo Therapeutics Announces Joint Research Collaboration with Q Therapeutics, Inc.

Fundamental Numbers:

Based on last reported financials, the company’s return on assets is -132.31% and price-to-book is 1.00.

Company Score Card:

Results are out of six:
 3  : Growth Expectations Result
 3  : Financial Safety Result
 0  : Past Performance Result
 2  : Valuation Result
 0  : Dividend Safety Result
 2  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here